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Summary
Only mismatch repair (MMR)-deficient colorectal cancer (CRC) appears to respond well to PD-1 inhibition at the present time. Emerging evidence suggests a role for micro-environmental factors such as CD25+ve cells modulating response to PD-1 inhibition. In the ApcMin/+ model of familial adenomatous polyposis (MMR-proficient CRC), increased Cyclooxygenase-2 (Cox-2) expression by alternatively-activated mononuclear phagocytes promotes intestinal tumorigenesis by mechanisms which may include immune suppression. To gain insight into this, we compared regulatory T-cell (Treg) populations between ApcMin/+ and wild-type mice prior to and after the phase of increased intestinal Cox-2-dependent PGE2 production. There was no difference in systemic Treg function or numbers between ApcMin/+ and wild-type mice. However, increased numbers of small intestinal CD25+ve Tregs were observed with increased Cox-2 activity in the absence of any difference in the expression of Tgf- or Tslp between ApcMin/+ and wild-type mice. Cox-2 inhibitor therapy (Celecoxib) reversed the increase in ApcMin/ + intestinal CD25+ve Treg numbers, without decreasing numbers of CD25+ve systemic Tregs. Foxp3+ve and Cox-2+ve cells were co-localized to the interstitium of adenomas of ApcMin/+ mice. These results suggest selective dependence of an ‘activated Treg’ phenotype on paracrine Cox-2 activity in ApcMin/+ small intestine. For therapeutic potential, further studies are required to evaluate the relevance of these findings to human cancer as well as the functional significance of CD25+ve intestinal Tregs in cancer.





Introduction:
Systemic therapy has led to some improvement in survival for patients with advanced colorectal cancer (CRC) over the past few decades, however,  it remains a major cause of cancer-related mortality in the Western world (1). Therapeutic reversal of PD-1/PD-L1 pathway mediated cancer immune suppression has recently emerged as a potent therapeutic target in some forms of cancer, but has not been effective for the majority of metastatic CRC except for those with mismatch repair (MMR) deficiency (2). This observation is surprising as there are relatively similar levels of PD-L1 expression between MMR-proficient and MMR-deficient cancers (3). A lower mutational burden resulting in reduced neo-epitopes in MMR-proficient cancer has been hypothesized as one factor explaining reduced responsiveness to antagonism of immunosuppression (2). However, emerging evidence suggests that tumour immune alterations beyond PD-L1 expression may also modulate responsiveness to PDL-1/PD-1 pathway antagonism. A recent study reported significantly enhanced response to PD-1 inhibition following depletion of CD25+ve cells (4). 

Cyclooxygenase-2 (Cox-2) over expression is ubiquitously associated with intestinal adenomas of familial adenomatous polyposis (FAP) (5) and over 70% of sporadic colorectal adenomas (6).  However, up to half of MMR-deficient CRC may not over express Cox-2 (7), while lower levels of Cox-2 overexpression have been reported for the others (8). In contrast to most other mammalian tissues where Cox-2 is an inducible gene, Cox-2 is constitutively expressed by intestinal lamina propria mononuclear cells (LPMNCs) where it has been shown to play a role in the establishment of dietary immune tolerance (9). The observation that PGE2 can induce regulatory phenotype in CD4+ve T-lymphocytes (Tregs) (10) has suggested a mechanism for Cox-2 in immune suppression. We have previously shown that intestinal LPMNC Cox-2 dependent PGE2 production increases in C57BL/6 mice after the age of weaning (~ 4 weeks of age), with further up-regulation of intestinal LPMNC Cox-2 dependent PGE2 production in the ApcMin/+ model of FAP during the phase of appearance of macroscopic adenomas (11). Our study and others (12, 13) have suggested that mononuclear phagocytes including macrophages, and sub-epithelial myofibrobalsts and vascular endothelial cells are the predominant source of intestinal Cox-2 expression dependent PGE2 production in the Apc mutant miceMin/+ mouse. Furthermore, CD4-Treg adoptive transfer paradoxically led to intestinal adenoma regression and reduced Cox-2 expression in the ApcMin/+ model (13). On the other hand, adoptive transfer of naive CD4+  T lymphocytes had the opposite effect of promoting intestinal tumorigenesis in the ApcMin/+ mouse in association with inflammatory mononuclear infiltrates (14). This has suggested potential interaction between Tregs and mononuclear phagocytes in the intestinal micro-environment to modulate intestinal tumorigenesis.

To yield insight into the role of Cox-2 expression in intestinal immune changes, we compared intestinal regulatory CD4-lymphocyte populations between ApcMin/+, Cox-2 inhibitor treated ApcMin/+ and wild-type mice.  We also studied Treg association with Cox-2 expressing cells.






Materials and Methods
Animals: All animal work was carried out with appropriate UK Home Office and local ethical committee approval. ApcMin/+ and Apc+/+ (wild-type) mice on the C57BL/6 background obtained from the Jackson’s laboratory (ME, USA) were bred according to UK Home Office guidelines under specific pathogen-free conditions at the University of Edinburgh and had free access to water and a standard RM1 diet (DBM, UK). Some ApcMin/+ mice were fed an RM1™  diet containing 300 parts per million (ppm) of Celecoxib (Pfizer, NJ, USA) from weaning (approximately 4 weeks of age) until analysis. 

Adenoma counts and intestinal epithelial or lamina propria mononuclear cell isolation: Mice were killed by a schedule 1 method (cervical dislocation). Intestinal adenomas were counted macroscopically by OF blinded to mouse diet. After removing visible Peyer’s patches, intestinal LPMNCs were isolated as previously described (9). LPMNC viability was assessed by trypan blue staining. Viability generally ranged between 75 and 85%. Intestinal epithelial cells obtained during the EDTA (Invitrogen, Paisley, UK) incubation phase of LPMNC isolation were lysed in TRIZOL™ (Invitrogen) and stored at -20C for Real-Time PCR analysis. LPMNCs obtained after enzymatic digestion of residual intestinal tissue were washed in PBS containing 5% foetal calf serum (FCS) (Sigma, Poole, UK) and used for flow cytometric analysis.

Tissue processing: Mice at ~ 4 (range: 4-5) or  15 (range: 14-16) weeks of age were culled and small intestine dissected out from the pylorus to the ileo-caecal junction. Intestinal lumina were flushed out with PBS till no luminal content was evident. The intestinal tissue was then opened longitudinally, segments fixed in methacarn (60% methanol, 30% chloroform and 10% glacial acetic acid) were dehydrated in ethanol and embedded in wax. 5m sections were obtained from wax embedded tissue. 

Immunohistochemistry (IHC): 
Foxp3: Anti-Foxp3 antibody (e-Bioscience, Hatfield, UK) and anti-CD3 antibody (DAKO, Ely, UK) IHC staining was carried out on methacarn fixed tissue as described (14). Antigen retrieval was by means of Borg decloaker (Biocare Medical, CA, USA).   Foxp3 staining was visualised with diaminobenzidine (DAB from DAKO) and CD3 with Vector blue (Vector Labs, Peterborough, UK). The number of positive cells for either of these markers was determined by counting from 10 alternate villi in distal small intestine. Anti-TGF- antibody (R&D systems, Abingdon, UK) IHC was carried out as previously described and developed with DAB (15).  Single stained sections were counterstained with Mayer’s Haematoxylin.

Dual Immunohistochemistry:
Cox-2: Methacarn-fixed intestinal sections were stained with 10µg/ml of affinity-purified Rabbit anti-mouse Cox-2 antibody [160126] (Cayman Chemicals, MI, USA) overnight at 4C. Controls included Cox-2 antibody mixed with ten-times its concentration of its competing peptide (360106, Cayman Chemicals). An anti-rabbit secondary antibody was used, with development of staining with DAB (16). Sections were then washed in PBS, and underwent Foxp3 immunohistochemistry as described above, except that staining was developed with alkaline phosphatase rather than DAB.

Flow Cytometry:
Cell surface markers: ~ 5x105 inguinal lymph node (ILN) or intestinal mononuclear cells were re-suspended in FACS buffer (2% FCS). After an Fc block (BD Biosciences, Oxford, UK) for 30 minutes, cells were labeled with CD4-FITC (2.5g/ml) and/or CD25-PE (1.25g/ml) or concentration matched isotype control (all e-Biosciences) for 30 min and then washed in FACS buffer. Intracellular staining was then carried out. 

Intracellular staining: ~ 5x105 ILN or intestinal mononuclear cells were re-suspended in FACS buffer (2% FCS). After Fc blocking as above, cells were labeled with surface markers or concentration matched isotype control (e-Biosciences) for 30 min and washed in FACS buffer. Cells were then fixed and permeabilised using the regulatory T-cell flow cytometry kit (e-Biosciences) according to the manufacturer’s instructions. Susbsequently, cells were stained with Foxp3-Apc (1.25g/ml) or concentration matched isotype control (e-Biosciences) with or without an antibody to Helios (Helios-Alexa Fluor 647, from BioLegend, CA, USA) or concentration matched isotype control as per manufacturer’s instructions. Cells were then washed and re-suspended in FACS buffer.
Flow cytometry data acquisition was carried out on a FACSCalibur (BD Biosciences) using Cell Quest software. Cells within a viable lymphocyte gate were analysed with Flo Jo software. 

Regulatory T-lymphocyte isolation and functional assays: ILN and spleens were obtained by dissection and passed through 40m filters (BD Biosciences, Oxford, UK) into 5% FCS in PBS. Splenic and ILN mononuclear cells were washed in 5% FCS and CD4+veCD25+ve (regulatory) and CD4+veCD25-ve (helper-inducer) populations were isolated using a regulatory T-cell isolation kit (Miltenyi Biotec, Surrey, UK) according to the manufacturer’s instructions. 5 x 104 CD4+veCD25-ve cells/well in 96-well tissue culture plates were stimulated with CD3/CD28 microbeads (Invitrogen) according to the manufacturer’s instructions and then cultured alone or with an equal number of CD4+veCD25+ve cells. Unstimulated CD4+veCD25-ve cells served as controls. Cultures were pulsed with 1Ci 3H-thymidine (Perkin Elmer, Cambridge, UK) per well after 72 hours and then incubated for a further 24 hours, after which the plates were frozen at -20C till harvested and incorporated 3H-thymidine counted in a -scintillation counter.

Real-Time PCR analysis: RNA was isolated from cells lysed in TRIZOL as advised by the manufacturer. Subsequently, cDNA was generated using a reverse transcription kit (Invitrogen). Genomic contamination was excluded using intron spanning primers to Cox-1 (Forward – CAC AGT GCG GTC CAA CCT TAT, Reverse – GAT GTA GTC ATG CGC TGA GTT GT) and looking for genomic-DNA sized PCR products on 2% agarose gels. Otherwise, Real-Time PCR was carried out with the following primers: Hprt (Forward – TGA AAG ACT TGC TCG AGA TGT CA; Reverse- CAC ACA GAG GGC CAC AAT GT), Tgf-1 (Forward – GCA GTG GCT GAA CCA AGG A; Reverse – AGC AGT GAG CGC TGA ATC G) and Tslp (Forward - CCC TGG CTG CCC TTC ACT; Reverse – CAT TGA GGG CTT CTC TTG TTC TC). All PCR primers were obtained from Invitrogen. PCR was then carried out on an Applied Biosystems 7700 machine using SYBR-green dye for fluorescence detection. PCR conditions were an annealing temperature of 60C for 30s, then amplification for 60s at 72C for 40 cycles followed by 72C for 10 minutes. The level of expression of Tgf-1 (Tgf-) or Tslp was normalized to the house-keeping gene Hprt.

Statistics: Group data is summarized and presented as the mean value  standard error of the mean. Data were analysed by Mann-Whitney using Prism™ software. Differences were considered statistically significant at a p-value of  0.05.














Results

1)	Increased numbers of Foxp3+ve small intestinal T-lymphocytes in ApcMin/+ compared with wild-type mice: We compared regulatory T-cell (Foxp3-expressing cell) numbers between ApcMin/+ (n=3) and wild-type (n=3) mouse small intestine at 15-weeks of age. CD3 (as a pan-T-lymphocyte marker) was used to control for the total number of T-lymphocytes. Double IHC showed that all Foxp3+ve cells were also CD3+ve (Figure 1B). Foxp3+ve cells were localized to the lamina propria (LP) of intestinal villi in ApcMin/+ and wild-type mice (Figure 1B). However, Foxp3+ve cells were also localized to the interstitium of intestinal adenomas in ApcMin/+ mice, particularly in a sub-epithelial location (shown later in Figure 3). The number of Foxp3+ve cells per villus in ApcMin/+ mouse small intestine was more than double the number observed in wild-type littermates despite no significant difference in the number of CD3+ve cells (Figure 1D, E). Consequently, we demonstrate increased numbers of Foxp3+ve T-lymphocytes in ApcMin/+ mouse intestine with established adenomas.
2)	 Increased proportion of ApcMin/+ mouse Foxp3+ve small intestinal lymphocytes with age: We then compared LP and ILN populations between ApcMin/+ and wild-type mice at 4 and 15 weeks of age (Figure 2) in order to determine if the increased Foxp3+ve lymphocyte population of ApcMin/+ small intestine occurred with age (during the phase of increased Cox-2 dependent PGE2 production), furthermore if populations in the intestine reflected those in unconnected lymphoid tissue. 
The Foxp3+ve proportion of LP or ILN lymphocytes was similar between ApcMin/+ and wild-type mice at 4 weeks of age (Figure 2D). However, there was a significantly increased proportion of Foxp3+ve LP lymphocytes in ApcMin/+ mice (p = 0.012) but not wild-type mice (p= 0.19) between 4 and 15 weeks of age (Figure 2E). In particular, a significantly increased proportion of Foxp3+ve LP lymphocytes was observed in ApcMin/+ compared with wild-type mice at 15 weeks of age (p = 0.019) with no significant difference in the proportion of Foxp3+ve ILN lymphocytes (Figure 2E). 
Alterations in the intestinal CD8 T-lymphocyte population of the ApcMin/+ mouse during tumorigenesis have been reported (17). We therefore determined the CD4+ve population of regulatory T-lymphocytes in ApcMin/+ mice. CD4 and Foxp3 expression by LP or ILN lymphocytes of ApcMin/+ and wild-type mice were analyzed (Figure 2F and G). The CD4+ve proportion of Foxp3+ve LP or ILN lymphocytes (Range: 81 – 91%) was similar between ApcMin/+ and wild-type mice. Consequently, during the phase of increased Cox-2 dependent PGE2 production; we demonstrated an increased (predominantly CD4+ve) regulatory intestinal lymphocyte population in ApcMin/+ mice. Changes of a similar nature were not observed in inguinal lymph nodes.

3)	An increased CD25+ve regulatory T-lymphocyte population during tumorigenesis in ApcMin/+ mouse intestine: IL-2 receptor-alpha (CD25) is a low affinity IL-2 receptor expressed by Tregs and activated lymphocytes (18). We therefore analyzed Foxp3 and CD25 expression by LP CD4-lymphocytes of ApcMin/+ and wild-type mice to determine the phenotype of the increased Treg population occurring during the phase of increased Cox-2 expression (Figure 2 H and I). 
As previously observed, a significantly increased CD4+veFoxp3+ve proportion of LP lymphocytes was observed in 15-week old ApcMin/+ compared with wild-type mice (Figure 2I). Even though the CD25+ve proportion of CD4+veFoxp3+ve lymphocytes was reduced in wild-type intestine compared to ILN (Figure 2 H and I), the CD25+ve proportion of CD4+veFoxp3+ve LP lymphocytes was higher in 15-week old ApcMin/ + than wild-type mice (p = 0.002) (Figure 2I). Consequently, there are increased numbers of CD25+ve Tregs in ApcMin/+ mouse intestine.

4)	Cox-2-inhibitor therapy inhibits small intestinal tumorigenesis and prevents the increase in CD4+veFoxp3+veCD25+ve lymphocytes in the ApcMin/+ mouse: We initially determined if Cox-2 inhibitor therapy (with Celecoxib 300 ppm) prevented intestinal tumorigenesis in ApcMin/+ mice as previously described (15).  Figure 3A shows that Celecoxib treatment led to an 85% reduction in intestinal adenoma numbers in ApcMin/+ mice.  
We then determined the effect of Cox-2 inhibition on the Treg population of 15-week old ApcMin/+ mice. Celecoxib therapy had no significant effect on the CD25+ve proportion of the CD4+veFoxp3+ve ILN lymphocytes (Figure 3B). However, the increased CD25+ve proportion of CD4+veFoxp3+ve LP lymphocytes of ApcMin/+ compared with wild-type mice was reduced by Celecoxib treatment (Figure 3C). This suggested that the increased CD25+ve Treg population of ApcMin/ + mice was dependent on Cox-2 activity. Notably, there was no significant difference in the proportion of CD4+veFoxp3+ve intestinal lymphocytes between Cox-2 inhibitor treated ApcMin/+ mice (24.56  0.59%; n=4) and those fed a control diet (24.12  2.18%; n=8) (p=0.933). This suggested that even though Cox-2 inhibition decreased the CD25+ve intestinal Treg population, it did not decrease the total intestinal Treg population.

5)	Foxp3 and Cox-2 expressing cells are co-localized to the interstitium of ApcMin/+ small intestinal adenomas: The distribution of Foxp3+ve cells in this study (Figs 1 and 3) was similar to the distribution of Cox-2 +ve cells in our previous study (11) and those of others (12). Therefore, to substantiate the possibility of paracrine interaction between Tregs and Cox-2 expressing mononuclear phagocytes, we carried out co-immunohistochemistry for Foxp3 and Cox-2 expression on intestinal adenomas of ApcMin/+ mice. Foxp3 and Cox-2 expressing cells were co-localized to the interstitium of intestinal adenomas (Figure 3G).
6)	No impairment of CD4-regulatory T-lymphocyte function in ApcMin/+ mice: Lymphocytic developmental defects have been described in mice with constitutive -catenin signaling (19) such as occurs in Apc mutant mice. We therefore tested for possible defective function of ApcMin/+ mouse CD4+ve regulatory T-cells accounting for their increased numbers in the immune active intestinal micro-environment. CD4+veCD25-ve (helper) and CD4+veCD25+ve (regulatory) T-lymphocytes were isolated from splenic and ILN lymphocytes of ApcMin/+ mice (n=3) and wild-type mice (n=3) at 15 weeks of age. The percentage suppression of CD3CD28-induced T-lymphocyte proliferation by regulatory T-lymphocytes was 62.8  16.1% for ApcMin/+ compared to 59.9  9.1% for wild-type mice. Therefore, we did not observe any impairment of ApcMin/+ mouse peripheral Treg functional ability.

7)	Helios expression by intestinal regulatory lymphocytes of ApcMin/+ mice:  Helios expression has been reported to stabilize Treg function (20). We further characterized the increased intestinal Tregs occurring after the phase of increased Cox-2 dependent PGE2 production in ApcMin/+ mice (Figure 4). We compared Helios expression by LP Tregs of 15-week old ApcMin/+ and wild-type mice (Figure 4). Among CD4+veFoxp3+ve LP lymphocytes, a significantly increased Helios+ve population was observed in ApcMin/+ compared with wild-type mice (p=0.029) (Fig 4E). Furthermore, among CD4+veCD25+ve LP lymphocytes, increased Helios expression in ApcMin/+ compared with wild-type mice (p = 0.029) was observed (Fig 4F). This suggested that induced Tregs during the phase of Cox-2 dependent PGE2 production were predominantly CD25+ve and Helios+ve in ApcMin/+ mice. In contrast, no significant differences were observed in the Helios +ve lymphocyte populations between ILN lymphocytes of ApcMin/+ and wild-type mice (data not shown). 

8)	Tslp and Tgf- expression by small intestinal epithelial cells of ApcMin/+ and wild-type mice at different ages: We then compared known molecular signals to Treg generation between ApcMin/+ and wild-type mice. We compared small intestinal epithelial Tgf- (21) and Tslp (22) mRNA expression prior to and after the period of increased Cox-2 dependent PGE2 production. Increased Tgf- mRNA expression was observed between 4 and 15 weeks of age in ApcMin/+ and wild-type mice (Figure 5A) but levels of Tgf- mRNA expression were similar between ApcMin/+ and wild-type mice at either age tested.  In contrast, we observed a trend towards decreased small intestinal epithelial Tslp mRNA expression between 4 weeks and 15 weeks of age in ApcMin/+ and wild-type mice, but no difference in levels of Tslp mRNA expression between ApcMin/+ and wild-type mice at either age tested (Figure 5B).










Discussion
To the best of our knowledge, this is the first description of an association between Cox-2 activity and Treg phenotypic variation during intestinal tumorigenesis in the ApcMin/+ model. We show an increased predominantly CD4+ve ApcMin/+ small intestinal Treg population with age during the phase of adenoma development. This is consistent with previous reports of increased Tregs in the tumor micro-environment (23). Similarly, we previously showed induction of human Tregs in vitro by a small-cell lung cancer cell line (24). Perhaps the most important finding was a Cox-2 dependent increased CD25+ve intestinal Treg population which is Helios+ve. We also demonstrate co-localization of Tregs and Cox-2 expressing mononuclear phagocytes. These taken together suggest that paracrine interaction between Cox-2 expressing mononuclear phagocytes and Tregs in ApcMin/+ mouse intestine modulate the Treg phenotype.
 
Determining the functional significance of phenotypic observations reported here as well as the relationship between Cox-2 expression and PD-1/PDL-1 expression were beyond the scope of this study. However, diphtheria-toxin mediated Foxp3 expressing cell depletion in the ApcMin/+ mouse has been reported to increase intestinal T-lymphocyte infiltrates and promote a pro-inflammatory milieu (26). Nevertheless, the functional significance of the CD25+ve Treg population in the intestinal immune microenvironment is not known. Tthe recent observation that antibody mediated depletion of CD25+ve cells in a mouse model enhanced response to PD-1 antagonism suggests their potential in vivo relevance. CD25-null mice (IL-2Rα-null) had reduced sensitivity to IL-2 which compromised T-lymphocyte function associated with polyclonal expansion of T-lymphocytes (25). With respect to Tregs, it is known that IL-2R–STAT5 mediated signaling generates activated STAT5 which is essential for stabilization of Foxp3 expression by binding the conserved noncoding sequence 2 (CNS2) region of the Foxp3 promoter (26). Additionally, the ikaros transcription factor Helios is known to have STAT5b as one of its principal targets in mice, stabilizing STAT5-dependent IL-2 responsiveness (20). The observation that constitutive STAT5b activation increased intestinal adenoma size in the ApcMin/+ mouse is consistent with a role for IL-2R –STAT5 Treg activation in promoting intestinal tumorigenesis (27). Noteworthy is the fact that constitutive STAT5b activation abrogated pro-inflammatory cytokine secretion while modifying expression of cell surface molecules by T-lymphocytes (27). These taken together suggest that abrogation of an increased intestinal CD25+ve Treg population during tumorigenesis in ApcMin/+ mice by Cox-2 inhibition could impair Treg function, thus countering tumour immunosuppression. Our observation that the CD25+ve Treg population of unconnected lymph nodes is not increased during tumorigenesis and unaffected by Cox-2 inhibition suggests selectivity of the LP Treg phenotypic modification as a potential therapeutic target, compared to non-specific ablation of the CD25+ve population.
 
With regards to underlying mechanisms, the observation of an increased proportion of CD25-ve LP Tregs and increased intestinal epithelial Tgf-β expresson with age in wild-type mice would be consistent with generation of adaptive Tregs by Tgf-β activity in intestinal immune tolerance (28). However, there was no increase in levels of Tgf-β expression in ApcMin/+ compared with wild-type small intestine to explain the further increase in the number of CD25-ve Tregs observed with the inhibition of Cox-2 activity. The observation that Cox-2 inhibition is known to suppress the growth of adenomas greater than 1mm in size but does not abrogate adenoma growth completely may explain this (29). Consequently, one explanation for increased CD25-ve Tregs in ApcMin/+ with Cox-2 inhibition could be increased Tgf-β derived from an increased number of intestinal epithelial cells within adenomas rather than increased levels of Tgf-β expression in ApcMin/+ mice. However, an alternative tumour specific signal to LP Treg generation during the process of tumorigenesis (which was not the purpose of this study) cannot be excluded. With reference to our observations, it has been proposed that in different circumstances, Tgf-β can generate Tregs via diverse molecular pathways [dependent on or independent of CD25 signaling] (30).  Furthermore, a previous study showed conversion of CD25-veTregs to CD25+veTregs by Tgf-β to mediate immunosuppression in tumours (31).  Of possible relevance to this is the fact that Tgf-β has been shown to induce alternative activation of mononuclear phagocytes (32). Our study suggests that Cox-2 inhibition reverses paracrine effects of alternately activated macrophages to enhance CD25 expression in Tregs of the ApcMin/+ intestinal micro-environment.
 
With regards to determining the clinical relevance of observations reported here, it would be important to determine if the phenotypic Treg change observed with Cox-2 inhibition in ApcMin/+ intestine applies to CRC tumours and/or metastases in humans. Furthermore, future studies will need to define the functional significance of loss of the Treg IL-2 receptor with Cox-2 inhibition in ApcMin/+ intestinal tumour micro-environment.  These could help determine if there is a role for Cox-2 inhibition in enhancing immunotherapy for CRC.
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